Navigation Links
Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting

SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced findings from its development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). The findings suggest measurable differences in the expression of particular biomarkers in blood samples between IBS and non-IBS patients. The identification of these biomarkers, combined with a proprietary algorithm, led to the development of PROMETHEUS IBS Diagnostic. These findings were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Orlando, Florida.

"PROMETHEUS IBS Diagnostic is an exciting advancement in the field of functional gastrointestinal disease," said Dr. Anthony Lembo, M.D., a gastroenterologist in the Division of Gastroenterology at Beth Israel Deaconess Medial Center and an Assistant Professor of Medicine at Harvard Medical School. "This test complements current symptom-based diagnostic practices by identifying patients with biomarker patterns consistent or inconsistent with IBS."

Following an extensive analysis of approximately 600 to 700 pathways, each containing hundreds of potential IBS biomarkers, Prometheus scientists identified 16 biomarkers that showed sufficient altered expression. The expression levels of these 16 biomarkers were then measured in a sample cohort of more than 1,700 patients and analyzed to reveal optimal IBS prediction with a final set of 10 biomarkers, including some that enable Prometheus' proprietary protection. These biomarkers are associated with one or more of the following pathways related to digestion: motility, brain-gut axis, neuronal regulation and immune function.

"IBS can be very difficult to definitively diagnose and is therefore often left untreated," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "PROMETHEUS IBS Diagnostic is the first in a series of tests we are developing for this complex syndrome. It provides physicians a valuable tool to help clarify or validate other clinical findings. This test further strengthens our growing portfolio of proprietary, high-value diagnostics and complementary pharmaceutical products."

IBS can be challenging to diagnose because it is a functional disease that is not associated with any visible abnormality and symptoms often overlap with other gastrointestinal conditions, such as inflammatory bowel disease, celiac disease and chronic functional constipation/diarrhea. Symptom-based criteria have been established to make a positive diagnosis of IBS; however, in practice the diagnosis of IBS is typically made through a process of elimination by determining the patient does not have other gastrointestinal diseases with similar symptoms.

About IBS

According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2007, almost 60 million, or 20%, of the U.S. population had symptoms of IBS, making it one of the most common disorders diagnosed by physicians. At least twice as many women as men are affected by IBS, a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. Although it significantly impairs health-related quality of life, unfortunately, many people suffer from IBS for almost 3 years before being properly diagnosed and treated. It is believed that up to 75% of people suffering from IBS are not receiving medical care for their symptoms, due in part to the current difficulties of diagnosing IBS.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.

SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
7. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
11. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):